Seer (SEER) Q2 Revenue Jumps 32%

Seer (NASDAQ:SEER) reported Q2 2025 GAAP revenue of $4.1 million, a 32% year-over-year increase that exceeded analyst expectations by 9.3%. The life sciences technology firm also reduced operating expenses by 21%, narrowing its net loss to $19.4 million from $22.9 million in the prior year. This performance was driven by strong product sales and strategic partnerships, including a new collaboration with Korea University, although the company remains unprofitable and reaffirmed its full-year 2025 revenue guidance of $17-$18 million amidst ongoing macroeconomic pressures.

Analysis

Seer's Q2 2025 results indicate solid commercial execution and improving operational discipline, yet highlight the ongoing challenges of a pre-profitability growth company. The firm reported a 32% year-over-year revenue increase to $4.1 million, exceeding consensus estimates by a significant 9.3%. This top-line strength was driven by product sales and strategic collaborations, notably a new 20,000-sample study with Korea University and an expanding partnership with Thermo Fisher Scientific, which helps validate its proteomics platform. Concurrently, a 21% reduction in operating expenses, aided by lower stock-based compensation, helped narrow the GAAP net loss to $19.4 million from $22.9 million in the prior year. Despite these positives, fundamental risks persist. Gross margin contracted to 52% from 56% year-over-year, moving away from the company's long-term target of 70-75%. Management reaffirmed full-year revenue guidance of $17-$18 million but acknowledged macroeconomic pressures, particularly on its academic and government customer base, which constitutes approximately 30% of revenue. With a cash and investments balance of $263.3 million, the company's cash burn rate remains a critical metric to monitor against its persistent net losses.

Key Decisions for Investors

• Investors with a higher risk tolerance may view the strong revenue beat and narrowing losses as evidence of a successful commercialization strategy, justifying a long position based on the growth trajectory.
• It is critical to monitor gross margin performance in subsequent quarters, as a failure to reverse the recent decline to 52% could signal underlying issues with pricing power or cost of goods, challenging the long-term profitability thesis.
• Potential investors should closely track the company's cash burn relative to its $263.3 million in cash and investments, as well as any signs of slowing customer adoption due to the noted macroeconomic headwinds on academic budgets.
• The progress of major partnerships, such as the large-scale Korea University cancer study, should be considered a key near-term catalyst for de-risking the technology and unlocking further market adoption.